Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology
PUBLISHED Thursday, March 5, 2026 · canada newswire
AI BRIEFING
- ⬤ Hydreight Technologies Inc. announces investment in Insu Therapeutics to advance needle-free peptide delivery technology.
- ⬤ The investment aims to accelerate the development of Insu Therapeutics' peptide delivery platform.
- ⬤ The collaboration will focus on bringing innovative treatments to patients with chronic diseases.
ADVERTISEMENT